GLPG Research | Milton Maxwell

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

FY Q3 '25

Q&A fleshes out BD, Gilead focus

11/5/25Nov 5, 2025

Q&A largely reaffirms the prepared shift to BD after failed cell therapy sale, but surfaces specifics: funnel targets mid-to-late stage oncology and immunology assets, prioritizing Gilead synergies. Cash flow turns neutral-to-positive by end-2026 via interest, royalties, and tax credits, post-wind down. TYK2 partnering paused near early-2026 data; post-results, they'll assess divestiture. Analysts flagged Gilead decision speed and BD capacity; management admitted complexity but touted team expertise and discipline. No rush on deals. Watch Q1 works council close and inaugural transactions.

Key Stats

Market Cap

2.05B

P/E (TTM)

-

Basic EPS (TTM)

-7.91

Dividend Yield

0%

About

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

CEO

Mr. Henry Gosebruch

IPO

2/27/2012

Website

https://www.glpg.com

Employees

704

Sector

Healthcare

Industry

Biotechnology